Cargando…
Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients
Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Inte...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777407/ https://www.ncbi.nlm.nih.gov/pubmed/36553141 http://dx.doi.org/10.3390/diagnostics12123134 |
_version_ | 1784856096009093120 |
---|---|
author | Escudero, Dolores Fernández-Suarez, Jonathan Forcelledo, Lorena Balboa, Salvador Fernández, Javier Astola, Ivan Quindos, Brigida Campos, Rainer Vázquez, Fernando Boga, José Antonio |
author_facet | Escudero, Dolores Fernández-Suarez, Jonathan Forcelledo, Lorena Balboa, Salvador Fernández, Javier Astola, Ivan Quindos, Brigida Campos, Rainer Vázquez, Fernando Boga, José Antonio |
author_sort | Escudero, Dolores |
collection | PubMed |
description | Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Intensive Care Unit (ICU), detecting 78 pathogens in 59 (41%) samples. The molecular panel was evaluated by using the conventional culture (CC) as comparator, which isolated 42 pathogens in 40 (27.7%) samples. The overall percentage of agreement was 82.6%. Values of sensitivity (93%), specificity (62%), positive predictive value (50%), and negative predictive value (96%) were obtained. The mean time elapsed from sample extraction to modification of antibiotic treatment was 7.6 h. A change in antimicrobial treatment after the FAPP+ results was performed in 27% of patients. The FAPP+ is a highly sensitive diagnostic method that can be used to significantly reduce diagnostic time and that allows an early optimization of antimicrobial treatment. |
format | Online Article Text |
id | pubmed-9777407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97774072022-12-23 Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients Escudero, Dolores Fernández-Suarez, Jonathan Forcelledo, Lorena Balboa, Salvador Fernández, Javier Astola, Ivan Quindos, Brigida Campos, Rainer Vázquez, Fernando Boga, José Antonio Diagnostics (Basel) Article Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Intensive Care Unit (ICU), detecting 78 pathogens in 59 (41%) samples. The molecular panel was evaluated by using the conventional culture (CC) as comparator, which isolated 42 pathogens in 40 (27.7%) samples. The overall percentage of agreement was 82.6%. Values of sensitivity (93%), specificity (62%), positive predictive value (50%), and negative predictive value (96%) were obtained. The mean time elapsed from sample extraction to modification of antibiotic treatment was 7.6 h. A change in antimicrobial treatment after the FAPP+ results was performed in 27% of patients. The FAPP+ is a highly sensitive diagnostic method that can be used to significantly reduce diagnostic time and that allows an early optimization of antimicrobial treatment. MDPI 2022-12-12 /pmc/articles/PMC9777407/ /pubmed/36553141 http://dx.doi.org/10.3390/diagnostics12123134 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Escudero, Dolores Fernández-Suarez, Jonathan Forcelledo, Lorena Balboa, Salvador Fernández, Javier Astola, Ivan Quindos, Brigida Campos, Rainer Vázquez, Fernando Boga, José Antonio Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients |
title | Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients |
title_full | Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients |
title_fullStr | Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients |
title_full_unstemmed | Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients |
title_short | Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients |
title_sort | evaluation and clinical impact of biofire filmarray pneumonia panel plus in icu-hospitalized covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777407/ https://www.ncbi.nlm.nih.gov/pubmed/36553141 http://dx.doi.org/10.3390/diagnostics12123134 |
work_keys_str_mv | AT escuderodolores evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT fernandezsuarezjonathan evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT forcelledolorena evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT balboasalvador evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT fernandezjavier evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT astolaivan evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT quindosbrigida evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT camposrainer evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT vazquezfernando evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients AT bogajoseantonio evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients |